Yaima Luzardo Lightfoot

Yaima Luzardo Lightfoot

Auto-generated profile, based on publicly available information

Yaima Luzardo Lightfoot

The Neurodegeneration Consortium, UT MD Anderson Cancer Center, Houston, TX USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
WRWilliam T. Ralvenius
William T. Ralvenius
AMAlison E. Mungenast
Alison E. Mungenast
HWHannah Woolf
Hannah Woolf
MHMargaret M. Huston
Margaret M. Huston
TGTyler Z. Gillingham
Tyler Z. Gillingham
LTLi-Huei Tsai
Li-Huei Tsai
Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.

13 July 2012
Verified
Book Chapter
Closed access
PDF file
YLYaíma L. Lightfoot
Yaíma L. Lightfoot
JCJing Chen
Jing Chen
CMClayton E. Mathews
Clayton E. Mathews

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SGSunil Goodwani
Sunil Goodwani
YLYaima Luzardo Lightfoot
Yaima Luzardo Lightfoot
BFBianca Gabrielle Ford
Bianca Gabrielle Ford
OCOlivia Calderon
Olivia Calderon
MMMorgan McReynolds
Morgan McReynolds
WRWilliam J Ray
William J Ray
Background: RIP Kinase 1 (RIPK1) is known to regulate necroptotic cell death in response to pro‐inflammatory signaling in cells where apoptotic signaling has been compromised. Aberrant RIPK1 activation has been implicated in several neurodegenerative disorders such as Alzheimer’s disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.Method: To investigate the role of RIPK1 in regulating the microglial response to demyelination, we administered a highly selective CNS penetrant RIPK1 inhibitor to C57Bl6 mice fed with cuprizone. We studied the microglial response using RNA Sequencing, single‐cell RNA Sequencing, lipidomics, and proteomics.Result: Transcriptomic analysis of isolated microglia and brain cytokine levels revealed that rapid demyelination induced by Cuprizone diet led to a strong disease‐associated microglia (DAM) response. Of the 1957 transcripts regulated in isolated microglia (padj<0.05) by the demyelination, RIPK1 inhibition significantly attenuated the microglial transcriptomic response of 497 transcripts (padj<0.1). Single‐cell RNA Sequencing analysis revealed that RIPK1 inhibition modified demyelination‐associated microglial sub‐clusters. Furthermore, soluble TREM2, a marker of microglia activation, was reduced, as were several cytokines in the brain. Open field analysis of these mice showed that RIPK1 inhibition rescued Cuprizone‐induced motor impairment. Proteomics and lipidomics analyses demonstrated RIPK1‐dependent changes in brain lipid metabolism.Conclusion: RIPK1 signaling promotes an inflammatory response that involves modulation of key regulatory pathways associated with demyelinating disorders.